logo-loader
Arcturus Therapeutics

Full interview: Arcturus Therapeutics working to 'transform the pharmaceutical industry' with its therapeutics

Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) CEO Joseph Payne tells Proactive that the company which specializes in developing messenger RNA medicine for rare diseases, is working towards 'transforming the pharmaceutical industry' with its therapeutics.

Payne says San Diego-based Arcturus has four therapeutics in pre-clinical studies, including its lead therapeutics LUNAR-CF and LUNAR-OTC. He is pleased with how its 2Q financial highlights are propelling these programs into the clinic.

Quick facts: Arcturus Therapeutics

Price: $12.30

Market: NASDAQ
Market Cap: $175.57 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: hVIVO PLC's 2020 pipeline 'looking strong' as it expands...

hVIVO PLC's (LON:HVO) executive chairman Trevor Phillips tells Proactive London's Andrew Scott the business is now better positioned to be profitable next year. The creator of pioneering human disease models based upon viral challenge generated revenues of £5.9mln in the six months ended June...

7 hours, 28 minutes ago

2 min read